Read by QxMD icon Read

Addiction treatment

shared collection
320 papers 1000+ followers
By Christopher Cook, BA,CADC, SAP Addiction professional. LPC, CADC, CRNP- student, Interventionist, project manager, owner, Director, eval/refer for SUDs/Eating D/o's
Beth Wiese, Adrianne R Wilson-Poe
Introduction: The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains pervasive. Discussion: Although there are a number of FDA-approved opioid replacement therapies and maintenance medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful for all patients...
2018: Cannabis and Cannabinoid Research
Mark K Greenwald
Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for the most commonly abused substances). I evaluate neuropharmacological mechanisms in experimental models of drug-maintenance and relapse, which translate more readily to individuals presenting for treatment (who have initiated and progressed)...
November 2018: Neurobiology of Stress
Helen E Jack, Devin Oller, John Kelly, Jessica F Magidson, Sarah E Wakeman
No abstract text is available yet for this article.
September 18, 2018: American Journal of Medicine
Ningning Guo, Xianwen Zhang, Mengbing Huang, Xiang Li, Ye Li, Xiaoshuang Zhou, Jie Bai
Morphine is widely used for clinical pain management and induces the dependence. Addiction to morphine is a major public health issue. Geranylgeranylacetone (GGA) is widely used in clinic for treating ulcer. GGA induces expression of thioredoxin-1 (Trx-1) extensively. Trx-1 is a redox regulating protein and plays protecting roles in nervous system. GGA prevents mice against morphine-induced hyperlocomotion, rewarding effect, and withdrawal syndrome. However, whether GGA blocks morphine-conditioned place preference (CPP) reinstatement is still unknown...
September 18, 2018: Neuropharmacology
Scott E Hadland, Tae Woo Park, Sarah M Bagley
BACKGROUND: Opioid-related overdose deaths have risen sharply among young adults. Despite this increase, access to evidence-based medication for opioid agonist treatment (OAT) for youth remains low. Among older adults, barriers to OAT include the paucity of buprenorphine-waivered prescribers and low rates of prescribing among waivered physicians. We have increasingly found in our clinical practice significant stigma related to using OAT to treat addiction for young adults. In this series, we describe three cases of young adults who faced significant stigma related to their treatment...
May 7, 2018: Addiction Science & Clinical Practice
Kathryn Hawk, Gail D'Onofrio
The emergency department (ED) has long been recognized as providing critical access to the health care system for many, yet only in the past few decades has the ED visit been recognized as an opportunity to identify and link patients to care for substance use disorders (SUDs). This review explores the evidence for ED-based screening, psychosocial and pharmacological interventions, and linkage to treatment for the spectrum of SUDs including high risk alcohol use and alcohol, opioid, tobacco and other SUDs. Despite knowledge gaps, methodological challenges and some inconsistency across interventions studied, opportunities for EDs to improve the care of patients across the spectrum of SUDs are robust...
August 6, 2018: Addiction Science & Clinical Practice
Katie Witkiewitz
No abstract text is available yet for this article.
September 11, 2018: Addiction
Gerhard Bühringer
No abstract text is available yet for this article.
September 12, 2018: Addiction
Olakunle J Onaolapo, Adejoke Y Onaolapo
Melatonin is a pleiotropic signalling molecule that regulates several physiological functions, and synchronises biological rhythms. Recent evidences are beginning to reveal that a dysregulation of endogenous melatonin rhythm or action may play a larger role in the aetiology and behavioural expression of drug addiction, than was previously considered. Also, the findings from a number of animal studies suggest that exogenous melatonin supplementation and therapeutic manipulation of melatonin/melatonin receptor interactions may be beneficial in the management of behavioural manifestations of drug addiction...
June 28, 2018: World Journal of Psychiatry
Gal Yadid, Hadas Ahdoot-Levi, Tzofnat Bareli, Rachel Maayan, Abraham Weizman
Drug addiction has a great negative influence on society, both social and economic burden. It was widely thought that addicts could choose to stop using drugs if only they had some self-control and principles. Nowadays, science has changed this view, defining drug addiction as a complex brain disease that affects behavior in many ways, both biological and psychological. Currently there is no ground-breaking reliable treatment for drug addiction. For more than a decade we are researching an alternative approach for intervention with drug craving and relapse to its usage, using DHEA, a well-being and antiaging food supplement...
2018: Vitamins and Hormones
Scott C Farrow, Mohamed O Kamileen, Jessica Meades, Belinda Ameyaw, Youli Xiao, Sarah E O'Connor
Monoterpenoid indole alkaloids are a large (∼3000 members) and structurally diverse class of metabolites restricted to a limited number of plant families in the order Gentianales. Tabernanthe iboga or iboga (Apocynaceae) is native to western equatorial Africa and has been used in traditional medicine for centuries. Howard Lotsof is credited with bringing iboga to the attention of Western medicine through his accidental discovery that iboga can alleviate opioid withdrawal symptoms. Since this observation, iboga has been investigated for its use in the general management of addiction...
September 7, 2018: Journal of Biological Chemistry
Murat Yücel, Erin Oldenhof, Serge H Ahmed, David Belin, Joel Billieux, Henrietta Bowden-Jones, Adrian Carter, Samuel R Chamberlain, Luke Clark, Jason Connor, Mark Daglish, Geert Dom, Pinhas Dannon, Theodora Duka, Maria Jose Fernandez-Serrano, Matt Field, Ingmar Franken, Rita Z Goldstein, Raul Gonzalez, Anna E Goudriaan, Jon E Grant, Matthew J Gullo, Robert Hester, David C Hodgins, Bernard Le Foll, Rico S C Lee, Anne Lingford-Hughes, Valentina Lorenzetti, Scott J Moeller, Marcus R Munafò, Brian Odlaug, Marc N Potenza, Rebecca Segrave, Zsuzsika Sjoerds, Nadia Solowij, Wim van den Brink, Ruth J van Holst, Valerie Voon, Reinout Wiers, Leonardo F Fontenelle, Antonio Verdejo-Garcia
BACKGROUND: The US National Institutes of Mental Health Research Domain Criteria (RDoC) seek to stimulate research into biologically validated neuropsychological dimensions across mental illness symptoms and diagnoses. The RDoC framework comprises 39 functional constructs designed to be revised and refined, with the overall goal of improving diagnostic validity and treatments. This study aimed to reach a consensus among experts in the addiction field on the 'primary' RDoC constructs most relevant to substance and behavioural addictions...
August 22, 2018: Addiction
Kshitij S Jadhav, Veronica L Peterson, Olivier Halfon, Grace Ahern, Fiona Fouhy, Catherine Stanton, Timothy G Dinan, John F Cryan, Benjamin Boutrel
Identifying biological markers predicting vulnerability to develop excessive alcohol consumption may lead to a real improvement of clinical care. With converging evidence suggesting that gut microbiome is capable of influencing brain and behavior, this study aimed at investigating whether changes in gut microbiome composition is associated with conditioned responses to alcohol. We trained Wistar rats to self-administer alcohol for a prolonged period before screening those exhibiting uncontrolled alcohol seeking and taking by modeling diagnostic criteria for AUD: inability to abstain during a signaled period of reward unavailability, increased motivation assessed in a progressive effortful task and persistent alcohol intake despite aversive foot shocks...
October 2018: Neuropharmacology
Irantzu Rico-Barrio, Sara Peñasco, Nagore Puente, Almudena Ramos, Christine J Fontaine, Leire Reguero, Maria Elvira Giordano, Ianire Buceta, Itziar Terradillos, Leire Lekunberri, Juan Mendizabal-Zubiaga, Fernando Rodríguez de Fonseca, Inmaculada Gerrikagoitia, Izaskun Elezgarai, Pedro Grandes
Binge drinking (BD) is a common pattern of ethanol (EtOH) consumption by adolescents. The brain effects of the acute EtOH exposure are well-studied; however, the long-lasting cognitive and neurobehavioral consequences of BD during adolescence are only beginning to be elucidated. Environmental enrichment (EE) has long been known for its benefits on the brain and may serve as a potential supportive therapy following EtOH exposure. In this study, we hypothesized that EE may have potential benefits on the cognitive deficits associated with BD EtOH consumption...
August 14, 2018: Addiction Biology
Ainsley M Sutherland, Judith Nicholls, James Bao, Hance Clarke
There is significant overlap in the pharmacological management of pain and psychological disorders. Appropriate treatment of patients' comorbid psychological disorders, including sleep disturbances often leads to an improvement in reported pain intensity. The three first line agents for neuropathic pain include tricyclic antidepressants and serotonin norepinephrine reuptake inhibitors which are medications originally developed as antidepressants. The other first line medication for chronic neuropathic pain are anticonvulsant medications initially brought to the market-place for the treatment of epilepsy and are also now being used for the treatment of anxiety disorders and substance withdrawal symptoms...
December 20, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
Ashley M Blouin, Swathi Pisupati, Colton G Hoffer, Madalyn Hafenbreidel, Sarah E Jamieson, Gavin Rumbaugh, Courtney A Miller
Human studies of substance use disorder show that psychological stress and drug availability interact following rehabilitation, contributing to the high relapse potential. Social stressors trigger particularly strong motivation for drug, but how this affects neuronal function to increase relapse is unknown. Animal models, which allow for the dissection of neural mechanisms, primarily utilize physical stressors to trigger relapse. To recapitulate psychosocial post-rehabilitation challenges in animals, we developed a model of social stress-potentiated methamphetamine (METH) seeking...
August 14, 2018: Addiction Biology
Anette Søgaard Nielsen
No abstract text is available yet for this article.
August 16, 2018: Addiction
Marta Peciña, Jordan F Karp, Sanjay Mathew, Mark S Todtenkopf, Elliot W Ehrich, Jon-Kar Zubieta
The United States is in the midst of an opioid addiction and overdose crisis precipitated and exacerbated by use of prescription opioid medicines. The majority of opioid prescriptions are dispensed to patients with comorbid mood disorders including major depressive disorder (MDD). A growing body of research indicates that the endogenous opioid system is directly involved in the regulation of mood and is dysregulated in MDD. This involvement of the endogenous opioid system may underlie the disproportionate use of opioids among patients with mood disorders...
June 28, 2018: Molecular Psychiatry
Arvin Haj-Mirzaian, Shayan Amiri, Hossein Amini-Khoei, Arya Haj-Mirzaian, Arsalan Hashemiaghdam, Kiana Ramezanzadeh, Maria Ghesmati, Khashayar Afshari, Ahmad Reza Dehpour
Abrupt discontinuation of chronic amphetamine consumption leads to withdrawal symptoms including depression, anhedonia, dysphoria, fatigue, and anxiety. These irritating symptoms may result in continuing to take the drug or can lead to suicidal behavior. Past studies have shown the involvement of various biologic systems in depression induced following amphetamine withdrawal (AW). However, there is no evidence about the relation between nitric oxide (NO) with NMDA receptors on depression following AW. In this study, we examined the involvement of the NO/NMDA pathways on depressive-like behaviors after 24 h withdrawal following 5 continuous days of amphetamine administration in male NMRI mice...
May 2018: Brain Research Bulletin
Stephen Butler
Background There are a number of false myths about buprenorphine based on unconfirmed animal data, even from isolated animal organs, and early clinical research. These myths came into textbooks on pharmacology and pain about 30 years ago and have been difficult to eradicate. Animal models of pain and pain relief are notoriously unreliable as predictors of human clinical effects. The fact is that in clinical practice there is NO bell-shaped dose-response curve, there is NO plateau on the dose-response curve, and there is NO antagonist effect from buprenorphine on other mu-opioid agonists...
July 1, 2013: Scandinavian Journal of Pain
2018-09-01 14:57:21
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"